EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 348 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ESMO Targeted Anticancer Therapies Congress 2023 February 24, 2023 Better together: improving brain tumour treatment February 13, 2023 Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated,... January 30, 2026 Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients... October 18, 2021 Load more HOT NEWS What Do “Health Equity” and “Quality Care” Mean in Cancer Care? 8-Year-Old Cancer Survivor Breaks National Record for Girl Scout Cookie Sales EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell...
